Brief: Plus Therapeutics Granted U.S. FDA Orphan Drug Designation For Rhenium (186Re) Obisbemeda
06/03/2025 12:50
March 6 (Reuters) - Plus Therapeutics PSTV.O: PLUS THERAPEUTICS GRANTED U.S. FDA ORPHAN DRUG DESIGNATION FOR RHENIUM (186RE) OBISBEMEDA FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES IN PATIENTS WITH LUNG CANCER Source text: ID:nGNX4VD5GD Further company coverage: PSTV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer